Insights
Search Results
Client Highlights
6.02.26
Wilson Sonsini Advises BVF Partners on IP Matters Related to Contraline’s $92.5 Million Series B
On June 2, 2026, Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. Wilson Sonsini Goodrich & Rosati advised BVF Partners on IP matters related to the transaction.
Client Highlights
5.11.26
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Client Highlights
9.10.25
Firm Advises Belite Bio on Patent Matters Related to $275 Million Private Placement
On September 10, 2025, Belite Bio, Inc., a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, announced that it has entered into securities purchase agreements with leading healthcare investors for a private placement in public equity financing (PIPE) that is expected to result in gross proceeds of approximately $125 million, before deducting placement agent fees and estimated offering expenses, and up to an additional approximately $150 million in gross proceeds if the accompanying warrants are fully exercised for cash. Wilson Sonsini Goodrich and Rosati advised Belite Bio on patent matters related to the transaction.
Client Highlights
9.05.25
Firm Advises Enlaza on IP Matters Related to Multi-Target Drug Discovery Collaboration with Vertex Pharmaceuticals
On September 2, 2025, Enlaza Therapeutics, the first covalent biologics platform company, announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia. Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the transaction.
Client Highlights
5.01.24
Wilson Sonsini Advises Enlaza Therapeutics on IP Matters Related to $100 Million Series A
On April 30, 2024, Enlaza Therapeutics (Enlaza), the first covalent biologic platform company, announced it successfully closed a $100 million Series A financing. The round was led by the Life Sciences group of J.P. Morgan Asset Management’s Private Capital division, with participation from existing investors Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital. The financing also includes new investors Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the Series A and represents the company in patent strategy and prosecution matters.
Client Highlights
12.22.23
Wilson Sonsini Advises K18 on Intellectual Property, Licensing, and Corporate Matters Related to Acquisition by Unilever
On December 22, 2023, Unilever, announced that it has entered into a definitive agreement to acquire premium biotech haircare brand K18. Wilson Sonsini Goodrich & Rosati is advising K18 on intellectual property, licensing, and corporate matters related to the transaction.